{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:25:32Z","timestamp":1761719132669},"reference-count":25,"publisher":"Japanese Society of Internal Medicine","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,10,1]]},"DOI":"10.2169\/internalmedicine.9039-21","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T22:12:11Z","timestamp":1645827131000},"page":"2853-2860","source":"Crossref","is-referenced-by-count":2,"title":["Vincristine, Doxorubicin, and Dexamethasone Induction before Autologous Stem Cell Transplantation in Patients with AL Amyloidosis: A Retrospective Comparison with Frontline Stem Cell Transplantation"],"prefix":"10.2169","volume":"61","author":[{"given":"Takashi","family":"Iijima","sequence":"first","affiliation":[{"name":"Nephrology Center, Toranomon Hospital Kajigaya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Sawa","sequence":"additional","affiliation":[{"name":"Nephrology Center, Toranomon Hospital Kajigaya, Japan"},{"name":"Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Nephrology Center, Toranomon Hospital Kajigaya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Oba","sequence":"additional","affiliation":[{"name":"Nephrology Center, Toranomon Hospital Kajigaya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Ikuma","sequence":"additional","affiliation":[{"name":"Nephrology Center, Toranomon Hospital Kajigaya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Nephrology Center, Toranomon Hospital Kajigaya, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Yamanouchi","sequence":"additional","affiliation":[{"name":"Nephrology Center, Toranomon Hospital Kajigaya, Japan"},{"name":"Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Suwabe","sequence":"additional","affiliation":[{"name":"Nephrology Center, Toranomon Hospital Kajigaya, Japan"},{"name":"Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Wake","sequence":"additional","affiliation":[{"name":"Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Japan"},{"name":"Department of Hematology, Toranomon Hospital Kajigaya, Japan"},{"name":"Department of Hematology, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Kono","sequence":"additional","affiliation":[{"name":"Department of Pathology, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Hoshino","sequence":"additional","affiliation":[{"name":"Nephrology Center, Toranomon Hospital Kajigaya, Japan"},{"name":"Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Ubara","sequence":"additional","affiliation":[{"name":"Nephrology Center, Toranomon Hospital Kajigaya, Japan"},{"name":"Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Ohashi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Toranomon Hospital, Japan"},{"name":"Department of Human Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Al Hamed R, Bazarbachi AH, Bazarbachi A, Malard F, Harousseau JL, Mohty M. Comprehensive review of AL amyloidosis: some practical recommendations. Blood Cancer J 11: 97, 2021.","DOI":"10.1038\/s41408-021-00486-4"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ash S, Shorer E, Ramgobin D, et al. Cardiac amyloidosis-a review of current literature for the practicing physician. Clin Cardiol 44: 322-331, 2021.","DOI":"10.1002\/clc.23572"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Matsuda M, Katoh N, Ikeda S. Clinical manifestations at diagnosis in Japanese patients with systemic AL amyloidosis: a retrospective study of 202 cases with a special attention to uncommon symptoms. Intern Med 53: 403-412, 2014.","DOI":"10.2169\/internalmedicine.53.0898"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 30: 4541-4549, 2012.","DOI":"10.1200\/JCO.2011.37.7614"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 26: 2317-2325, 2012.","DOI":"10.1038\/leu.2012.100"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Dispenzieri A., Lacy MQ, Kyle RA, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 19: 3350-3356, 2001.","DOI":"10.1200\/JCO.2001.19.14.3350"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 357: 1083-1093, 2007.","DOI":"10.1056\/NEJMoa070484"},{"key":"8","unstructured":"8. D'Souza A, Dispenzieri A, Wirk B, et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a center for international blood and marrow transplant research study. J Clin Oncol 33: 3741-3749, 2015."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Gertz MA, Lacy MQ, Dispenzieri A, et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 34: 1025-1031, 2004.","DOI":"10.1038\/sj.bmt.1704691"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Jeryczynski G, Antlanger M, Duca F, et al. First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience. ESMO Open 6: 100065, 2021.","DOI":"10.1016\/j.esmoop.2021.100065"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Basset M, Milani P, Nuvolone M, et al. Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis. Blood Adv 4: 4175-4179, 2020.","DOI":"10.1182\/bloodadvances.2020002219"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Cornell RF, Fraser R, Costa L, et al. Bortezomib-based induction is associated with superior outcomes in light chain amyloidosis patients treated with autologous hematopoietic cell transplantation regardless of plasma cell burden. Transplant Cell Ther 27: 264.e1-264.e7, 2021.","DOI":"10.1016\/j.jtct.2020.11.018"},{"key":"13","unstructured":"13. Y\u0131k\u0131lmaz A\u015e, Akinci S, Bakanay \u015eM, Dilek \u0130. VAD chemotherapy versus bortezomib containing regimens as remission induction for ASCT in multiple myeloma: a single center experience. Int J Hematol Oncol Stem Cell Res 14: 248-256, 2020."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sezer O, Eucker J, Schmid P, Possinger K. New therapeutic approaches in primary systemic AL amyloidosis. Ann Hematol 79: 1-6, 2000.","DOI":"10.1007\/s002770050001"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Osawa Y, Kawamura K, Kondo D, et al. Renal function at the time of renal biopsy as a predictor of prognosis in patients with primary AL-type amyloidosis. Clin Exp Nephrol 8: 127-133, 2004.","DOI":"10.1007\/s10157-004-0286-y"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Leung N, Dispenzieri A, Lacy MQ, et al. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation. Clin J Am Soc Nephrol 2: 440-444, 2007.","DOI":"10.2215\/CJN.02450706"},{"key":"17","first-page":"218","volume":"84","author":"V Perfetti","year":"1999","unstructured":"17. Perfetti V, Colli Vignarelli M, Anesi E, et al. The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients. Haematologica 84: 218-221, 1999.","journal-title":"Haematologica","ISSN":"http:\/\/id.crossref.org\/issn\/0390-6078","issn-type":"print"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Tandon N, Muchtar E, Sidana S, et al. Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival. Bone Marrow Transplant 52: 1126-1132, 2017.","DOI":"10.1038\/bmt.2017.68"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kon T, Nakagawa N, Yoshikawa F, et al. Systemic immunoglobulin light-chain amyloidosis presenting hematochezia as the initial symptom. Clin J Gastroenterol 9: 243-251, 2016.","DOI":"10.1007\/s12328-016-0664-5"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Siau K, Elzubeir A, Cooper SC, Iqbal T. Amyloidosis: an unusual cause of upper gastrointestinal bleeding. BMJ Case Rep 2016: bcr2016217653, 2016.","DOI":"10.1136\/bcr-2016-217653"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Varga C, Comenzo RL. High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review. Bone Marrow Transplant 54: 508-518, 2019.","DOI":"10.1038\/s41409-018-0284-4"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Sanchorawala V, Wright DG, Seldin DC, et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant 33: 381-388, 2004.","DOI":"10.1038\/sj.bmt.1704346"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Hazenberg BP, Croockewit A, van der Holt B, et al. Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology. Haematologica 100: 677-682, 2015.","DOI":"10.3324\/haematol.2014.119198"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Perz J. B., Schonland SO, Hundemer M, et al. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. Br J Haematol 127: 543-551, 2004.","DOI":"10.1111\/j.1365-2141.2004.05232.x"},{"key":"25","unstructured":"25. Kastritis E., Palladini G, Minnema MC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med 385: 46-58, 2021."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/19\/61_9039-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:21:15Z","timestamp":1715232075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/19\/61_9039-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":25,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9039-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,1]]},"article-number":"9039-21"}}